BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack

BIOCRYST PHARMACEUTICALS INC

Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.
The price increase applies to both the 150mg and 110mg capsule strengths.
BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis.

item 7.01

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-26-000154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.